Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Ther Clin Risk Manag
GHK-Cu (50mg), a copper-bound tripeptide first isolated from human blood plasma in 1973
Research shows the compound affects multiple metabolic parameters: Enhanced mitochondrial biogenesis through PGC-1 activation Improved fat oxidation capacity through metabolic gene expression changes Modulated inflammatory responses through nuclear receptor signaling Regulated circadian gene expression patterns 5-Amino-1MQ Mechanism The amino 1mq mechanism is centered on NNMT enzyme inhibition, giving researchers a different way to study metabolic regulation
Inflammatory and Protective Pathway Investigation: Exploring peptide involvement in cellular stress and protective signalling models
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Phase 2a liver-disease trial that adds human metabolic and safety context
US$ 26.98
:max_bytes(150000):strip_icc()/ozempic-GettyImages-2171479933-070be1d0cc1e4dcc9681c3eaa69497d0.jpg)
US$ 28.68
US$ 20.38
US$ 29.06
US$ 20.26
US$ 24.66
